Miller Craig S, Cunningham Larry L, Lindroth John E, Avdiushko Sergei A
Department of Oral Health Practice, University of Kentucky College of Dentistry and College of Medicine, Lexington 40536-0297, USA.
J Am Dent Assoc. 2004 Sep;135(9):1311-8. doi: 10.14219/jada.archive.2004.0407.
Oral herpes simplex virus, or HSV, infections recur after trauma and stress. The prevalence of these infections after dental procedures is not known. Also, it is unclear whether antiviral agents are effective in preventing dental procedure-induced HSV recurrences. This study determined the efficacy and safety of oral valacyclovir in suppressing dentally related cold sore outbreak and HSV shedding.
The authors enrolled 125 otherwise healthy HSV-seropositive adults who reported having recurrent herpes labialis (more than one episode per year and at least one episode in the previous year) in a randomized, double-blind, placebo-controlled study and gave them valacyclovir prophylactically (2 grams taken twice on the day of dental treatment and 1 g taken twice the next day) or a matching placebo. To detect the presence of the virus, the authors used clinical examinations, viral cultures and real-time polymerase chain reaction analysis of saliva.
During the one-week observation period after treatment, there were more clinical lesions (20.6 percent versus 11.3 percent), more HSV-1-positive culture specimens (7.9 percent versus 1.6 percent) and more HSV-1-positive saliva specimens (7.9 percent versus 4.0 percent) in placebo than in valacyclovir-treated patients, respectively. The percentage of patients who developed recurrences and shed HSV-1 in saliva 72 hours after dental procedures was significantly smaller in the valacyclovir group than in the placebo group (11.3 percent versus 27 percent; P = .026). The mean time to pain cessation was significantly less in the valacyclovir group (3.2 days) than in the placebo group (6.2 days) (P = .006).
HSV recrudescence after routine dental treatment is suppressed by valacyclovir prophylaxis.
HSV recrudescence is common after routine dental treatment. Clinicians should consider antiviral therapy for patients at risk of experiencing a recurrence, as well as to minimize transmission of the disease.
口腔单纯疱疹病毒(HSV)感染在创伤和应激后会复发。牙科手术后这些感染的发生率尚不清楚。此外,抗病毒药物是否能有效预防牙科手术引起的HSV复发也不明确。本研究确定了口服伐昔洛韦在抑制与牙科相关的唇疱疹发作和HSV脱落方面的疗效和安全性。
作者在一项随机、双盲、安慰剂对照研究中招募了125名其他方面健康的HSV血清阳性成年人,这些人报告有复发性唇疱疹(每年发作超过一次且上一年至少发作一次),并预防性给予他们伐昔洛韦(牙科治疗当天服用2克,分两次服用,第二天服用1克,分两次服用)或匹配的安慰剂。为了检测病毒的存在,作者采用了临床检查、病毒培养和唾液的实时聚合酶链反应分析。
在治疗后的一周观察期内,安慰剂组出现临床病变的患者比例(20.6%对11.3%)、HSV-1阳性培养标本比例(7.9%对1.6%)和HSV-1阳性唾液标本比例(7.9%对4.0%)均高于伐昔洛韦治疗组。牙科手术后72小时出现复发并在唾液中排出HSV-1的患者百分比,伐昔洛韦组明显低于安慰剂组(11.3%对27%;P = 0.026)。伐昔洛韦组疼痛停止的平均时间(3.2天)明显短于安慰剂组(6.2天)(P = 0.006)。
预防性使用伐昔洛韦可抑制常规牙科治疗后的HSV复发。
常规牙科治疗后HSV复发很常见。临床医生应考虑对有复发风险的患者进行抗病毒治疗,以及尽量减少疾病传播。